retatrutide phase 2 trial Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Online—Effects of #retatrutide on #body

What are GLP-1 Medications

The inclusion criteria explicitly excluded people with diabetes to isolate weight loss effects in the non-diabetic obese population

Cons of orforglipron At the highest (36mg) dose in ACHIEVE-1, 8% of trial participants discontinued usage owing to adverse events, with vomiting and nausea reported in 14% and 16% of participants respectively

Peter Kongstvedt, M.D., a senior health policy faculty member in the Department of Health Administration and Policy at George Mason University, told Fierce Healthcare in an email that the evidence is there that these drugs work to help people lose weight

In retatrutide research, the goal is not to use glucagon as an emergency treatment

Glucagon-like peptide-1 agonist drugs, such as semaglutide, could save countless lives at risk due to diabetes and obesity